GSK, Flagship Pioneering Commit $150M to Start R&D Pact for Novel Drugs and Vaccines

Pharmaceutical giant GlaxoSmithKline (GSK) is investing $150m upfront to team up with Flagship Pioneering, aiming to discover up to 10 new medicines and vaccines, initially for respiratory and immunology-related diseases. Under this deal, Flagship and its companies could receive $720m in milestone payments per programme, plus any sales royalties from future commercialised products.